515846-27-2

Basic information

• Product Name: (4-bromo-2,3-dichloro-phenoxy)-triisopropyl-silane
• Synonyms: (4-bromo-2,3-dichloro-phenoxy)-triisopropyl-silane
• CAS NO: 515846-27-2
• Molecular Weight: 398.243
• Mol File: 515846-27-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (4-bromo-2,3-dichloro-phenoxy)-triisopropyl-silane(CAS DataBase Reference)
• NIST Chemistry Reference: (4-bromo-2,3-dichloro-phenoxy)-triisopropyl-silane(515846-27-2)
• EPA Substance Registry System: (4-bromo-2,3-dichloro-phenoxy)-triisopropyl-silane(515846-27-2)

Safety Data

• Hazardous Substances Data: 515846-27-2(Hazardous Substances Data)

Upstream product

• 576-24-9 2,3-dichlorophenol 
• 13154-24-0 triisopropylsilyl chloride 
• 1940-44-9 4-bromo-2,3-dichlorophenol 

Downstream Products

• 515846-30-7 2,3-dichloro-4-triisopropylsilanyloxy-benzoic acid 
• 515846-52-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-methoxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery of a potent small molecule IL-2 inhibitor through fragment assembly

Using a site-directed fragment discovery method called tethering, we have identified a 60 nM small molecule antagonist of a cytokine/receptor interaction (IL-2/IL2Rα) with cell-based activity. Starting with a low micromolar hit, we employed a combination

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.